(PRWEB) February 07, 2013
Research Reports in Clinical Cardiology has published "Galectin-3: clinical utility and prognostic value in patients with heart failure". This review summarizes the key findings of fourteen clinical trials in which Galectin-3 (Gal-3) was assessed as a biomarker of heart failure in more than 16,900 patients. In addition, it provides the most relevant information available about gal-3 biology generated in in vitro and in vivo research.
Gal-3 biology and preclinical studies are reviewed, assessing its value as a biomarker in heart failure (HF). The author of this study evaluates the utility of gal-3 for diagnosis, clinical decision-making, monitoring, and in prediction of outcomes. According to journal editor-in-chief Dr Richard Kones, "While most authorities agree that gal-3 is a promising biomarker in HF, other than the strong predictive relationship with mortality in different patient populations, more work is needed for any of these uses to attain clinical recognition in the form of evidence-based recommendations."
Study author Frank Kramer, Clinical Sciences, agrees, "Since the most recent review on the role of Gal-3 in heart failure was published several years ago and various additional clinical studies assessing its utility for the management of cardiovascular disease were published since that, an update on this topic is urgently needed."
According to Kramer, the carbohydrate binding protein gal-3, which is expressed by cardiac fibroblasts and several other cell types and which can be quantified in serum or plasma samples, is a frequently discussed biomarker to ass
Copyright©2012 Vocus, Inc.
All rights reserved